EVFM · Evofem Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $899.0K | - | $4.95M | $4.83M | $845.0K | - | $4.50M | $4.16M | $3.60M | - |
| Cost of Revenue | $410.0K | - | $905.0K | $755.0K | $365.0K | - | $869.0K | $769.0K | $684.0K | - |
| Gross Profit | $489.0K | - | $4.05M | $4.07M | $480.0K | - | $3.63M | $3.39M | $2.92M | - |
| R&D | - | - | - | - | - | - | $332.0K | $270.0K | $594.0K | - |
| SG&A | $2.37M | - | $2.09M | $1.84M | $2.37M | - | $3.05M | $2.27M | $2.82M | - |
| Total Operating Expenses | $5.47M | - | $4.00M | $6.08M | $518.0K | - | $6.94M | $5.55M | $6.45M | - |
| D&A | $4.0K | - | - | - | $6.0K | - | $500.0K | $200.0K | $12.0K | - |
| Operating Income | ($4.57M) | - | $951.0K | ($1.25M) | $327.0K | - | ($2.44M) | ($1.39M) | ($2.84M) | - |
| Interest Expense | $614.0K | - | $599.0K | $588.0K | $577.0K | - | $556.0K | $546.0K | $564.0K | - |
| Income Tax | ($1.0K) | - | ($4.0K) | $7.0K | - | - | ($8.0K) | $8.0K | - | - |
| Net Income | ($5.46M) | - | ($1.57M) | ($1.78M) | $956.0K | - | ($2.37M) | $1.35M | ($4.81M) | - |
| EPS - Basic | ($0.04) | - | ($0.01) | ($0.02) | $0.01 | - | ($0.02) | $0.02 | ($0.16) | - |
| EPS - Diluted | ($0.04) | - | ($0.01) | ($0.02) | $0.00 | - | ($0.02) | $0.00 | ($0.16) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.49M | $578.0K | $840.0K | $748.0K | $221.0K | $741.0K | $410.0K | $636.0K | $689.0K | $580.0K |
| Accounts Receivable | $560.0K | $12.48M | $4.43M | $4.93M | $1.15M | $9.83M | $5.39M | $4.62M | $4.31M | $5.74M |
| Inventory | $1.89M | $1.13M | $1.68M | $1.91M | $2.26M | $1.58M | $1.46M | $1.06M | $1.31M | $1.70M |
| Accounts Payable | $12.00M | $13.15M | $11.62M | $12.29M | $11.22M | $16.17M | $16.86M | $16.03M | $16.29M | $17.02M |
| Current Assets | $6.06M | $15.28M | $7.92M | $8.97M | $5.87M | $13.61M | $8.58M | $7.21M | $6.92M | $9.21M |
| Total Assets | $7.44M | $20.27M | $13.81M | $14.38M | $12.88M | $23.79M | $23.94M | $8.55M | $8.22M | $10.55M |
| Current Liabilities | $78.75M | $84.82M | $78.19M | $73.89M | $70.85M | $80.45M | $76.29M | $73.18M | $74.24M | $72.46M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $80.15M | $89.71M | $83.98M | $79.21M | $77.68M | $90.26M | $90.07M | $73.18M | $74.24M | $72.47M |
| Stockholders' Equity | ($77.63M) | ($74.34M) | ($75.07M) | ($69.62M) | ($69.59M) | ($71.26M) | ($70.89M) | ($69.31M) | ($70.67M) | ($66.51M) |
| Retained Earnings | ($902.88M) | ($897.39M) | ($900.18M) | ($898.50M) | ($896.71M) | ($897.66M) | ($894.62M) | ($892.25M) | ($893.55M) | ($888.70M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.30M | - | - | - | $560.0K | - | - | - | $123.0K | - |
| Investing Cash Flow | ($2.0K) | - | - | - | ($57.0K) | - | - | - | ($14.0K) | - |
| Financing Cash Flow | ($498.0K) | - | - | - | ($135.0K) | - | - | - | - | - |
| CapEx | $2.0K | - | - | - | - | - | - | - | $14.0K | - |
| Free Cash Flow | $2.30M | - | - | - | - | - | - | - | $109.0K | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 54.4% | - | 81.7% | 84.4% | 56.8% | - | 80.7% | 81.5% | 81.0% | - |
| Operating margin | -508.2% | - | 19.2% | -25.9% | 38.7% | - | -54.3% | -33.4% | -78.9% | - |
| EBITDA margin | -507.8% | - | - | - | 39.4% | - | -43.1% | -28.6% | -78.6% | - |
| Net margin | -607.9% | - | -31.7% | -37.0% | 113.1% | - | -52.6% | 32.5% | -133.5% | - |
| Free cash flow margin | 255.7% | - | - | - | - | - | - | - | 3.0% | - |
| FCF / Net income | -0.42 | - | - | - | - | - | - | - | -0.02 | - |
| R&D / Revenue | - | - | - | - | - | - | 7.4% | 6.5% | 16.5% | - |
| SG&A / Revenue | 263.8% | - | 42.2% | 38.2% | 279.9% | - | 67.9% | 54.5% | 78.4% | - |
| Effective tax rate | - | - | - | - | - | - | - | 0.6% | - | - |
| Return on assets | -73.4% | - | -11.4% | -12.4% | 7.4% | - | -9.9% | 15.8% | -58.5% | - |
| Return on equity | 7.0% | - | 2.1% | 2.6% | -1.4% | - | 3.3% | -1.9% | 6.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.08 | 0.18 | 0.10 | 0.12 | 0.08 | 0.17 | 0.11 | 0.10 | 0.09 | 0.13 |
| Quick ratio | 0.05 | 0.17 | 0.08 | 0.10 | 0.05 | 0.15 | 0.09 | 0.08 | 0.08 | 0.10 |
| Cash ratio | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -7.4x | - | 1.6x | -2.1x | 0.6x | - | -4.4x | -2.5x | -5.0x | - |
| Equity multiplier | -0.10 | -0.27 | -0.18 | -0.21 | -0.19 | -0.33 | -0.34 | -0.12 | -0.12 | -0.16 |
| Liabilities / Assets | 10.77 | 4.42 | 6.08 | 5.51 | 6.03 | 3.79 | 3.76 | 8.56 | 9.04 | 6.87 |
| Efficiency | ||||||||||
| Asset turnover | 0.12 | - | 0.36 | 0.34 | 0.07 | - | 0.19 | 0.49 | 0.44 | - |
| Inventory turnover | 0.22 | - | 0.54 | 0.40 | 0.16 | - | 0.59 | 0.73 | 0.52 | - |
| Days sales outstanding | 227d | - | 327d | 373d | 496d | - | 438d | 405d | 436d | - |
| Days inventory outstanding | 1683d | - | 679d | 921d | 2263d | - | 614d | 503d | 697d | - |
| Days payable outstanding | 10686d | - | 4688d | 5942d | 11224d | - | 7083d | 7610d | 8695d | - |
| Cash conversion cycle | -8776d | - | -3682d | -4647d | -8465d | - | -6031d | -6702d | -7562d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 1.3x | - | 0.3x | 0.2x | 64.3x | - | 0.2x | 4.3x | 0.2x | - |
| EV / EBITDA | - | - | - | - | 162.6x | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 6.4% | - | 10.1% | 16.0% | -76.5% | - | -12.1% | 69.2% | -15.2% | - |
| Revenue CAGR (3y) | -40.4% | - | -8.1% | -7.2% | -41.6% | - | 38.0% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 1.9% | - | 11.6% | 20.0% | -83.6% | - | 12.5% | 1955.2% | 1.5% | - |
| Operating income growth (YoY) | - | - | - | 9.9% | - | - | 31.3% | 81.1% | 20.5% | - |
| Net income growth (YoY) | - | - | 33.7% | - | - | - | - | - | -104.3% | - |
| EPS growth (YoY) | - | - | 50.0% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -11.6% | -4.3% | -5.9% | -0.4% | 1.5% | -7.1% | -25.8% | -24.5% | -25.3% | 7.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$18.20M totalPhexxi$18.20M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Evofem Biosciences against the 5 most active filers in the same SIC group.